The Effects of Telmisartan and Amlodipine in Treatment-Naïve and Previously Treated Hypertensive Patients: A Subanalysis from a 4 × 4 Factorial Design Study

Abstract

The subanalysis of a 4 × 4 factorial, 8-week study to evaluate the efficacy and tolerability of telmisartan (T) 40-80 mg/amlodipine (A) 5-10 mg used in treatment-naïve patients (n = 231) and patients previously treated with antihypertensive agents (n = 880). Similar blood pressure (BP) reductions were achieved with T + A, regardless of their pretreatment status. Highest reductions were achieved with T80 + A10 (treatment-naïve -26.5/-18.2 mm Hg and previously treated -25.6/-19.9 mm Hg). Most patients (treatment-naïve 72.4% and previously treated 77.6%), including those with added risk, achieved BP goal (<140/90 mm Hg) with T80 + A10. Tolerability was comparable in both groups.

Protective effect of telmisartan on rats with renal failure and its mechanism

“…Telmisartan, belonging to ARB drugs, can control blood pressure through inhibiting renin-angiotensin-aldosterone system, which is widely used in the treatment of hypertension [5] . It is found that the structure of telmisartan has differences with other ARB drugs, and it has the activity of PPARg agonist [6] .…”

Partially protective effect of telmisartan on slow healing wounds in diabetic rats: possible role of AGEs-RAGE axis

“…Telmisartan, an angiotensin receptor blocker, is widely used in the treatment of hypertension (Punzi et al, 2013). Telmisartan is the most lipophilic drug of its class and has long half-life after oral administration (approximately 24 hours) (Plosker & White, 2008).…”